"ASX Healthcare Share Up 220% On Big News!"

Let's turn the blog section into free English with short sentences to make it easier to understand: The picture is from Getty Images. --------------------------------------------------- There are many things we can do to help the environment. --------------------------------------------------- One important action is reducing our use of single-use plastics. --------------------------------------------------- Single-use plastics are used only once and then thrown away. --------------------------------------------------- They can take hundreds of years to break down and harm animals and the environment. --------------------------------------------------- We can use reusable bags, bottles, and containers to reduce single-use plastic waste. --------------------------------------------------- Let's all do our part to protect the environment!

This is a blog post with different opinions from The Motley Fool's Premium Investing Services. If you join as a member, you can see our top analyst recommendations, research, and investing tools. It's easy to become a member. Learn more now!

Today, the ASX share market was not very good. The ASX: XAO finished with a big loss of 1.54%. However, there is one healthcare share on the ASX that did well and made its shareholders rich.

Zelira Therapeutics Ltd (ASX: ZLD) share price shot up today. It was 94 cents yesterday but closed at $3.05 a share today. That's 224.5% increase.

If you had $10,000 worth of Zelira shares yesterday, you now have over $30,000 worth today. It's true!

What's happening to this ASX healthcare share that made a huge impact on its investors?

ASX's Zelira Healthcare Shares Surge 220% Today – Why?

Investors might be grateful for the company's recent announcement. The announcement was made this morning.

Zelira has good news about their drug, ZLT-L-007. A clinical trial showed it can treat nerve pain. The results are positive. The trial just ended.

ZLT-L-007 beat Lyrica in reducing pain and symptoms. Lyrica is a big money drug.

The study said ZLT-L-007 is safe and didn't cause any bad things to happen.

Zelira is considering putting ZLT-L-007 into official FDA clinical trials. The decision is based on recent positive outcomes.

Zelira's chair, Osagie Imasogie, commented on some thrilling news for the company.

We used Lyrica as a reference to test our new pain medicine, ZLT-L-007. Lyrica makes a lot of money, so we knew the market was big. Our medicine was better than Lyrica and sometimes offered four times more pain relief.

We feel confident about evaluating ZLT-L-007 for formal FDA clinical trials due to this positive result.

Zelira, a healthcare company on the ASX, had a great day. Investors are thrilled. We're curious about what's next for the company.

Deeper Insights Into Health Stocks

"Top Healthcare Shares With Strong Growth Potential On ASX 200"

Date: May 30, 2023. Author: Tony Yoo. Rewritten: It's May 30th, 2023 and the author of this piece is Tony Yoo.

Experts have advice about the health industry in Australia. The industry is doing well. They have stock tips to share.

"Top Quality: 3 Reasons Why This ASX 200 Share Reigns In Australia"

Blog section: May 29, 2023 by Tristan Harrison Hi there! My name is Tristan Harrison. I wanted to share my writing with you today. Here goes! On May 29, 2023, I decided to write about my life and experiences. I am really excited to share them with you. I love to write because it allows me to express my thoughts and feelings. I also love to read because it opens up my mind to new ideas and perspectives. I hope that my writing can inspire others to take on new challenges and follow their dreams. Remember, never give up!

This healthcare company is highly profitable and it has good potential for growth.

Why Is ASX 300 Share Up 10% Today?

On May 26, 2023, James Mickleboro wrote a blog post.

On Friday, the company's shareholders will be happy.

ASX 200 Healthcare Stock Crashes: Reasons Explained

This is a blog post written by James Mickleboro on May 26, 2023.

This medical device company has had a difficult year. Their sales have been impacted by the pandemic. They have also faced manufacturing delays and supply chain interruptions. Despite these challenges, the company has remained resilient. They have adapted to the changing market and continued to innovate. The company is hopeful for a brighter future as the world recovers from the pandemic.

What Products Can Boost CSL Share Price?

On May 26, 2023, James Mickleboro wrote a blog post. He used short and simple sentences in his writing. This made the writing easy to understand. He shared his thoughts and ideas in a concise way. Readers found the blog post engaging and informative. James Mickleboro was able to convey his message effectively. Overall, it was a successful blog post.

What's happening in the labs of CSL?

"Top Healthcare Shares Set To Soar: Highly Sought-After"

On May 25, 2023, Tony Yoo wrote a blog post.

This industry was booming before COVID-19. An expert thinks it's going to boom again.

CSL Stock Forecast For H2 2023?

On May 19th, 2023, Tony Yoo wrote a blog section. Tony Yoo wrote a blog. It was written on May 19th, 2023. The author is Tony Yoo.

The biotech company's stock hasn't moved much since COVID-19 hit. Will it go up after the pandemic ends?

ASX Healthcare Share Surges 50% In 48 Hours: Why?

Today is May 18, 2023. The author of this blog is Monica O'Shea.

The biotech firm is doing well because of good clinical trial results.